Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
THURSDAY, Sept. 15, 2022 -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Neoadjuvant Therapy | Oral Cancer | Pharmaceuticals | Skin Cancer | Squamous Cell Carcinoma